P3–458: Effectivity of treatment of mild cognitive impaired subjects using rivastigmine: Functional MRI

Change-Plus (CIBIC-Plus) scores at endpoint (FAS-LOCF). They were assessed using ANCOVA for SIB and CMH test for CIBIC-plus. CIBICPlus was also analyzed using collapsed categories (1-3 improved; 4 no change; 5-7 worsened). Results: Donepezil 5-mg and 10-mg were significantly superior to placebo in SIB for FAS-LOCF (mean differences of 6.7 and 9.0 respectively from placebo, p 0.001) and for FAS-OC (p 0.001). Both CIBIC-Plus analyses showed statistically significant differences in favor of donepezil 10-mg over placebo for FAS-LOCF and FAS-OC (p 0.003, p 0.005, respectively). Collapsed analysis for CIBICPlus was similar to as follows; for FAS-LOCF (p 0.001) and for FAS-OC (p 0.001). Most AEs (94%) were mild or moderate. AEs reported more than 5% and twice of placebo were vomiting, elevated CK level, diarrhea, anorexia, fever, abrasion, constipation, loss of appetite and restlessness. Conclusions: The results of this study confirmed the superiority of donepezil 10-mg/d to placebo in severe AD patients on SIB and CIBIC-Plus. The administrations of 5-mg and 10-mg of donepezil for severe AD are safe and well tolerated.